Trial intelligence / Profile preview

Surufatinib Phase II in Chemotherapy-Refractory Thymic Malignancies

ChiCTR2600116776Phase 2Completed

Sponsor

Zhongshan Hospital, Fudan University

Start

Jan 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1